LM11A-31-BHS / PharmatrophiX - LARVOL DELTA

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 (clinicaltrials.gov) - P2 | N=147 | Not yet recruiting | Sponsor: Adam Boxer

New P2 trial • CNS Disorders • Movement Disorders • Progressive Supranuclear Palsy

New Considerations for Accelerating Combination Therapy Trials to be Showcased at 2024 Clinical Trials on Alzheimer’s Disease Conference (PRNewswire) - "The Alzheimer's Drug Discovery Foundation (ADDF) will be leading a roundtable, 'Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments,' at the 2024 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 29th through November 1st in Madrid, Spain...CTAD will feature several key sessions from ADDF-funded investigators, whose work in drug development and biomarkers is shaping and leading the field towards the holy grail of Alzheimer's treatments—combination therapy and precision medicine, similar to cancer care."

P1/2 data • P2 data • P2a data • Alzheimer's Disease • CNS Disorders

Study of LM11A-31-BHS in Mild-moderate AD Patients (clinicaltrials.gov) - P1/2; N=242; Completed; Sponsor: PharmatrophiX Inc.; Active, not recruiting ➔ Completed; Trial completion date: Sep 2020 ➔ Jun 2020

Clinical • Trial completion • Trial completion date • Alzheimer's Disease • CNS Disorders

[VIRTUAL] ALZHEIMER’S DRUG DEVELOPMENT PIPELINE: NOVEL TARGETS AND INNOVATIVE APPROACHES (AAT-ADPD 2020) - "Selected (non-exhaustive) examples of agents addressing these alternate pathways include: posiphen for presenilin processing; ALZ-801 and AAVrh.10hAPOE2 addressing ApoE-related biology; DHP1401, CT1812, LM11A-31-BHS, and AR1001 focus on synaptic function; levetiracetam, deferiprone, GV1001, and NDX-1017 for neuroprotection; COR388, niflamapimod (VX-745), and GV-971 for immunity and inflammation; AMX0035, AUS-131 and MP-101 for mitochondrial energetics; candesartan, telmisartan, and dabigatran for vascular factors; liraglutide, dapagliflozin, for metabolic dysfunction; MAPTRx/BIIB080 is an RNA-based intervention and vafidemstat and apabetalone are epigenetic interventions; and lupron, a hormonal intervention (gonadotropin-releasing hormone receptor agonist). One novel combination approach consists of losartan, amlodipine, atorvastatin and exercise and rasagiline is an example of molecule with pleiotropic effects on dopamine and disease-biology pathways...Novel designs..."

Alzheimer's Disease • CNS Disorders • APOE

Study of LM11A-31-BHS in Mild-moderate AD Patients (clinicaltrials.gov) - P1/2; N=242; Active, not recruiting; Sponsor: PharmatrophiX Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Oct 2019 ➔ Sep 2020; Trial primary completion date: Oct 2019 ➔ Jun 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date